Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Gut Année : 2018

Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab

Piyaporn Boonsirikamchai
  • Fonction : Auteur
Michael Overman
  • Fonction : Auteur
Mohamed Asran
  • Fonction : Auteur
Haesun Choi
  • Fonction : Auteur
Delise Herron
  • Fonction : Auteur
Cathy Eng
  • Fonction : Auteur
Dipen Maru
  • Fonction : Auteur
Jean-Nicolas Vauthey
  • Fonction : Auteur
Evelyne Loyer
  • Fonction : Auteur
Scott Kopetz
  • Fonction : Auteur
  • PersonId : 935913

Résumé

OBJECTIVE: The purpose was to validate the prognostic value of an early optimal morphological response on CT in patients treated with bevacizumab-containing chemotherapy for unresectable colorectal cancer liver metastases (CLM). It also evaluated the prognostic value of size-based criteria and the association of optimal morphological response with the receipt of bevacizumab. DESIGN: 141 patients treated first using bevacizumab and 142 patients from a randomised study evaluating the addition of bevacizumab to oxaliplatin-based chemotherapy were retrospectively analysed. Radiologists evaluated pretreatment and restaging CT scans using morphological response criteria. Responses were also assessed with size-based criteria: Response Evaluation Criteria in Solid Tumors (RECIST), early tumour shrinkage (ETS) and deepness of response (DpR). The ability of each criterion to predict progression-free survival (PFS), overall survival (OS) and postprogression survival (PPS) was determined using a univariate Cox proportional hazards model. RESULTS: In both populations, median PFS was significantly longer for patients achieving an optimal morphological response (10.4 vs 6.8 months, p=0.03; and 8.3 vs 4.9 months, p<00001, respectively). Neither RECIST nor ETS responses were associated with a prolonged PFS. Median OS was longer for those with an optimal morphological response but only at second restaging in the first population (n=141, 20.8 vs 12.3 months, p=0.002). DpR but not optimal morphological response was associated with PPS. In the randomised study, an optimal morphological response was 6.2 times more likely among patients receiving bevacizumab (p<0.0001). CONCLUSION: In patients with unresectable CLM, early morphological response may be a better predictor of PFS than size-based response. The addition of bevacizumab improves morphological response rate.
Fichier non déposé

Dates et versions

hal-02283080 , version 1 (10-09-2019)

Identifiants

Citer

Thibault Mazard, Piyaporn Boonsirikamchai, Michael Overman, Mohamed Asran, Haesun Choi, et al.. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut, 2018, 67 (6), pp.1095-1102. ⟨10.1136/gutjnl-2017-313786⟩. ⟨hal-02283080⟩
30 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More